uniQure N.V. - Ordinary Shares — datos financieros trimestrales (NASDAQ:QURE) | MetaTrader

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Flujo de caja de las actividades operativas -52.84 M-44.1 M-39.9 M-16.4 M-77.57 M-38.24 M -172.11 M Flujo de caja de las actividades de inversión -26.62 M20.1 M73.07 M26.58 M-441.37 M98.56 M -243.16 M Flujo de caja de las actividades financieras -6.52 M80.67 M44 K332.24 M2.45 M550 K 335.28 M Flujo de caja libre -52.84 M-44.1 M-40.16 M-16.33 M-77.69 M-38.38 M -172.56 M

Noticias

uniQure: Why A Shifting FDA Could Change Everything For AMT-130 (NASDAQ:QURE)

Las acciones de uniQure suben un 20% tras la noticia de la BLA de Replimune ante la FDA

Biotech Investors Are Tuning Out the MAHA Chaos

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure planea presentación en Reino Unido para terapia génica AMT-130 contra Huntington

Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks.com

Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?

PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors

A Unique Situation For UniQure (QURE)

Mizuho mejora la calificación de uniQure tras cambio en la FDA